Papillary thyroid carcinoma: ≤ 10 mm does not always mean pN0. A multicentric real-world study.
Lymph node metastasis
Papillary
Thyroid
Thyroid microcarcinoma
Journal
Updates in surgery
ISSN: 2038-3312
Titre abrégé: Updates Surg
Pays: Italy
ID NLM: 101539818
Informations de publication
Date de publication:
06 Mar 2024
06 Mar 2024
Historique:
received:
12
12
2023
accepted:
03
02
2024
medline:
6
3
2024
pubmed:
6
3
2024
entrez:
6
3
2024
Statut:
aheadofprint
Résumé
The incidence of papillary thyroid carcinoma (PTC) is increasing and PTC ≤ 10 mm (PTMC) accounts for most new diagnoses. PTMCs are not always low risk, as detection of lymph nodes metastasis (LNM) may occur. The purpose of the study was to analyze the clinical pattern, frequency, and independent risk factors of patients with PTMC and LNM. From January 2022 to June 2023, PTCs managed at CTO Hospital, Rome; Policlinico Vanvitelli, Naples; and Garibaldi Nesima Hospital, Catania were included. PTC management followed the same diagnostic-therapeutic procedures according to the ATA guidelines. Variables such as age, sex, maximum diameter, histologic evidence of LNM (HELNM +), Hashimoto's thyroiditis (HT), multifocality, capsule invasion, and histological subtype were considered. PTCs were divided according to HELNM and size. Two hundred ninety-eight PTCs were included. PTMCs were 136 (45.6%) and LNM occurred in 27.2% of them. In the HELNM + group, analysis of PTMC vs 'MacroPTC' (PTC > 10 mm) did not show any statistical difference. Multivariate regression revealed that young age (OR 0.93; CI 95% 0.90-0.96; p < 0.01) and male sex (male OR 3.44; CI 95% 1.16-10.20; p = 0.03) were the only independent risk factors for HELNM + in PTMC. The risk of LNM in PTMC is not negligible; therefore, a careful evaluation by an expert thyroidologist is mandatory for patients with small thyroid nodule, especially in younger and male patients before excluding surgery. In the future, new tools are needed to detect early PTMC with LNM before surgery.
Identifiants
pubmed: 38446376
doi: 10.1007/s13304-024-01779-6
pii: 10.1007/s13304-024-01779-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L (2016) Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med. 375(7):614–7. https://doi.org/10.1056/NEJMp1604412
doi: 10.1056/NEJMp1604412
pubmed: 27532827
Sutherland R, Tsang V, Clifton-Bligh RJ, Gild ML (2021) Papillary thyroid microcarcinoma: is active surveillance always enough? Clin Endocrinol (Oxf). 95(6):811–817. https://doi.org/10.1111/cen.14529
doi: 10.1111/cen.14529
pubmed: 34021503
Howlader N et al. (2019) SEER cancer statistics review, 1975–2016, National Cancer Institute. Bethesda.
Vigneri R, Malandrino P, Russo M (2020) Is thyroid cancer increasing in incidence and aggressiveness? J Clin Endocrinol Metab 105(7):dgaa223. https://doi.org/10.1210/clinem/dgaa223
doi: 10.1210/clinem/dgaa223
pubmed: 32369832
Chen DW, Lang BHH, McLeod DSA, Newbold K, Haymart MR (2023) Thyroid cancer. Lancet 401(10387):1531–1544. https://doi.org/10.1016/S0140-6736(23)00020-X
doi: 10.1016/S0140-6736(23)00020-X
pubmed: 37023783
Durante C, Hegedüs L, Czarniecka A et al (2023) 2023 European thyroid association clinical practice guidelines for thyroid nodule management. Eur Thyroid J 12(5):e230067. https://doi.org/10.1530/ETJ-23-0067
doi: 10.1530/ETJ-23-0067
pubmed: 37358008
pmcid: 10448590
Amendola S, WoldeSellasie S, Pedicini F et al (2023) Evaluation of the Performance of ACR TI-RADS Also Considering Those Nodules with No Indication of FNAC: A Single-Center Experience. J Clin Med. 12(2):398. https://doi.org/10.3390/jcm12020398
doi: 10.3390/jcm12020398
pubmed: 36675326
pmcid: 9865358
Wu X, Li B, Zheng C, He X (2023) Risk factors for skip metastasis in patients with papillary thyroid microcarcinoma. Cancer Med. 12(6):7560–7566. https://doi.org/10.1002/cam4.5507
doi: 10.1002/cam4.5507
pubmed: 36479912
Ruan J, Chen Z, Chen S et al (2023) Lateral lymph node metastasis in papillary thyroid microcarcinoma: a study of 5241 follow-up patients. Endocrine. https://doi.org/10.1007/s12020-023-03486-5
doi: 10.1007/s12020-023-03486-5
pubmed: 37922092
Roh JL, Kim JM, Il Park C (2008) Central cervical nodal metastasis from papillary thyroid microcarcinoma: pattern and factors predictive of nodal metastasis. Ann Surg Oncol 15(9):2482–2486. https://doi.org/10.1245/s10434-008-0044-6
doi: 10.1245/s10434-008-0044-6
pubmed: 18612697
Ito Y, Miyauchi A, Inoue H et al (2010) An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg 34(1):28–35. https://doi.org/10.1007/s00268-009-0303-0
doi: 10.1007/s00268-009-0303-0
pubmed: 20020290
Roti E, DegliUberti EC, Bondanelli M, Braverman LE (2008) Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol 159(6):659–673. https://doi.org/10.1530/EJE-07-0896
doi: 10.1530/EJE-07-0896
pubmed: 18713843
Hay ID, Hutchinson ME, Gonzalez-Losada T et al (2008) Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 144(6):980–988. https://doi.org/10.1016/j.surg.2008.08.035
doi: 10.1016/j.surg.2008.08.035
pubmed: 19041007
ChristoferJuhlin C, Mete O, Baloch ZW (2023) The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading. Endocr Relat Cancer. https://doi.org/10.1530/ERC-22-0293
doi: 10.1530/ERC-22-0293
Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133. https://doi.org/10.1089/thy.2015.0020
doi: 10.1089/thy.2015.0020
pubmed: 26462967
pmcid: 4739132
Liu C, Xiao C, Chen J et al (2019) Risk factor analysis for predicting cervical lymph node metastasis in papillary thyroid carcinoma: a study of 966 patients. BMC Cancer 19(1):622. https://doi.org/10.1186/s12885-019-5835-6
doi: 10.1186/s12885-019-5835-6
pubmed: 31238891
pmcid: 6593593
Wang Z, Gui Z, Wang Z et al (2023) Clinical and ultrasonic risk factors for high-volume central lymph node metastasis in cN0 papillary thyroid microcarcinoma: a retrospective study and meta-analysis. Clin Endocrinol (Oxf) 98(4):609–621. https://doi.org/10.1111/cen.14834
doi: 10.1111/cen.14834
pubmed: 36263602
Al Afif A, Williams BA, Rigby MH et al (2015) Multifocal papillary thyroid cancer increases the risk of central lymph node metastasis. Thyroid 25(9):1008–1012. https://doi.org/10.1089/thy.2015.0130
doi: 10.1089/thy.2015.0130
pubmed: 26161997
Huang XP, Ye TT, Zhang L et al (2018) Sonographic features of papillary thyroid microcarcinoma predicting high-volume central neck lymph node metastasis. Surg Oncol 27(2):172–176. https://doi.org/10.1016/j.suronc.2018.03.004
doi: 10.1016/j.suronc.2018.03.004
pubmed: 29937168
Wei X, Min Y, Feng Y et al (2022) Development and validation of an individualized nomogram for predicting the high-volume (> 5) central lymph node metastasis in papillary thyroid microcarcinoma. J Endocrinol Invest 45(3):507–515. https://doi.org/10.1007/s40618-021-01675-5
doi: 10.1007/s40618-021-01675-5
pubmed: 34491546
Zeng X, Wang Z, Gui Z et al (2021) High incidence of distant metastasis is associated with histopathological subtype of pediatric papillary thyroid cancer—a retrospective analysis based on SEER. Front Endocrinol (Lausanne). https://doi.org/10.3389/fendo.2021.760901
doi: 10.3389/fendo.2021.760901
pubmed: 35154000
Nardi F, Basolo F, Crescenzi A et al (2014) Italian consensus for the classification and reporting of thyroid cytology. J Endocrinol Invest 37(6):593–599. https://doi.org/10.1007/s40618-014-0062-0
doi: 10.1007/s40618-014-0062-0
pubmed: 24789536
Leenhardt L, Erdogan MF, Hegedus L, Mandel SJ, Paschke R, Rago T, Russ G (2013) 2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. Eur Thyroid J 2(3):147–59. https://doi.org/10.1159/000354537
doi: 10.1159/000354537
pubmed: 24847448
pmcid: 4017749
Filetti S, Durante C, Hartl D et al (2019) Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 30(12):1856–1883. https://doi.org/10.1093/annonc/mdz400
doi: 10.1093/annonc/mdz400
pubmed: 31549998
Pizzimenti C, Fiorentino V, Ieni A et al (2022) Aggressive variants of follicular cell-derived thyroid carcinoma: an overview. Endocrine 78(1):1–12. https://doi.org/10.1007/s12020-022-03146-0
doi: 10.1007/s12020-022-03146-0
pubmed: 35864338
Sugitani I (2023) Active surveillance of low-risk papillary thyroid microcarcinoma. Best Pract Res Clin Endocrinol Metab 37(1):101630. https://doi.org/10.1016/j.beem.2022.101630
doi: 10.1016/j.beem.2022.101630
pubmed: 35256266
Lee JS, Lee JS, Yun HJ et al (2023) Aggressive subtypes of papillary thyroid carcinoma smaller than 1 cm. J Clin Endocrinol Metab 108(6):1370–1375. https://doi.org/10.1210/clinem/dgac739
doi: 10.1210/clinem/dgac739
pubmed: 36546348
Cao Z, Zhang Z, Tang X et al (2022) Comprehensive analysis of tissue proteomics in patients with papillary thyroid microcarcinoma uncovers the underlying mechanism of lymph node metastasis and its significant sex disparities. Front Oncol 12:887977. https://doi.org/10.3389/fonc.2022.887977
doi: 10.3389/fonc.2022.887977
pubmed: 36106120
pmcid: 9465038
Aliyev E, Ladra-González MJ, Sánchez-Ares M et al (2020) Thyroid papillary microtumor. Am J Surg Pathol. 44(9):1161–1172. https://doi.org/10.1097/PAS.0000000000001522
doi: 10.1097/PAS.0000000000001522
pubmed: 32804453
Banu KS, Govindarajulu P, Aruldhas MM (2001) Testosterone and estradiol have specific differential modulatory effect on the proliferation of human thyroid papillary and follicular carcinoma cell lines independent of TSH action. Endocr Pathol. 12(3):315–328. https://doi.org/10.1385/EP:12:3:315
doi: 10.1385/EP:12:3:315
pubmed: 11740053
Jiang C, Xu F, Yi D et al (2023) Testosterone promotes the migration, invasion and EMT process of papillary thyroid carcinoma by up-regulating Tnnt1. J Endocrinol Invest. https://doi.org/10.1007/s40618-023-02132-1
doi: 10.1007/s40618-023-02132-1
pubmed: 38146045
pmcid: 10776714
Yu P, Qu N, Zhu R et al (2023) TERT accelerates BRAF mutant–induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis. Sci Adv. https://doi.org/10.1126/sciadv.adg7125
doi: 10.1126/sciadv.adg7125
pubmed: 38117891
pmcid: 10881033
Landa I (2023) InTERTwined: How TERT promoter mutations impact BRAFV600E-driven thyroid cancers. Curr Opin Endocr Metab Res 30:100460. https://doi.org/10.1016/j.coemr.2023.100460
doi: 10.1016/j.coemr.2023.100460
pubmed: 37576936
Mazzaferri EL (2007) Management of low-risk differentiated thyroid cancer. Endocr Pract 13(5):498–512. https://doi.org/10.4158/EP.13.5.498
doi: 10.4158/EP.13.5.498
pubmed: 17872353
Baek HS, Ha J, Kim K et al (2023) Cost-effectiveness of active surveillance compared to early surgery of small papillary thyroid cancer: a retrospective study on a korean population. J Korean Med Sci. https://doi.org/10.3346/jkms.2023.38.e264
doi: 10.3346/jkms.2023.38.e264
pubmed: 38084030
pmcid: 10782045
Frasca F, Piticchio T, Le Moli R et al (2022) (2022) Early detection of suspicious lymph nodes in differentiated thyroid cancer. Expert Rev Endocrinol Metab. 17(5):447–454. https://doi.org/10.1080/17446651.2022.2112176
doi: 10.1080/17446651.2022.2112176
pubmed: 35993330